Skip to main
TTRX

TTRX Stock Forecast & Price Target

TTRX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Turn Therapeutics is a platform dermatology company with multiple potential treatments for inflammatory and infectious skin diseases, backed by its proprietary PermaFusion technology. Its ongoing clinical study for GX-03 as a topical treatment for moderate-to-severe eczema follows promising preclinical evidence and a history of favorable tolerability for the same formula. With revision of assumptions accounting for a longer therapeutic course and a higher assumed price per course for onychomycosis, the company's overall long-term revenue contribution and forward-looking price target remain stable at $8.00.

Bears say

Turn Therapeutics is heavily reliant on its proprietary platform technology, PermaFusion, to drive future growth. However, the company's financial outlook is uncertain as they recently announced a new loan agreement with Avenue Venture for up to $25M which is tied to several milestone payments and has a discounted conversion feature. This could result in significant dilution for shareholders and may cause financial strain for the company in the future. Additionally, the company's only current product in development, GX-03, is still in the early stages of clinical trials and there is no guarantee of its success in treating eczema.

TTRX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Turn Therapeutics Inc (TTRX) Forecast

Analysts have given TTRX a Strong Buy based on their latest research and market trends.

According to 1 analysts, TTRX has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Turn Therapeutics Inc (TTRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.